Women First Healthcare, Inc.
The chapter 11 plan of Women First Healthcare, Inc. was approved by the United States Bankruptcy Court for the District of Delaware on December 21, 2004 and went into effect on January 18, 2005.
The successful approval of the chapter 11 plan was the culmination of intensive joint efforts by Young Conaway and Latham & Watkins LLP, working closely together as bankruptcy attorneys to the company, as well as Miller Buckfire Lewis Ying & Co., LLC, financial advisors and investment bankers to the company.
Women First was founded in 1996 as a specialty pharmaceutical company focused primarily on the increasing health needs of midlife women. At the time of it bankruptcy filing, the company had a portfolio consisting of seven prescription products addressing four main therapeutic areas: (i) unwanted facial hair, (ii) estrogen replacement therapy, (iii) migraines/pain relief, and (iv) bacterial infections. The company filed for chapter 11 bankruptcy protection on April 30, 2004 amidst significant liquidity constraints. After winning approval of its debtor-in-possession financing facility, Women First and its professionals engaged in extensive efforts to maximize asset value through liquidation efforts. Six of the pharmaceutical product lines were acquired through several spirited sales and auctions resulting in significantly higher value than originally projected. In accordance with the chapter 11 plan, a liquidating trustee has been appointed to, among other things, liquidate any remaining assets, prosecute avoidance actions and reconcile claims.
The successful approval of the chapter 11 plan was the culmination of intensive joint efforts by Young Conaway and Latham & Watkins LLP, working closely together as bankruptcy attorneys to the company, as well as Miller Buckfire Lewis Ying & Co., LLC, financial advisors and investment bankers to the company.
Women First was founded in 1996 as a specialty pharmaceutical company focused primarily on the increasing health needs of midlife women. At the time of it bankruptcy filing, the company had a portfolio consisting of seven prescription products addressing four main therapeutic areas: (i) unwanted facial hair, (ii) estrogen replacement therapy, (iii) migraines/pain relief, and (iv) bacterial infections. The company filed for chapter 11 bankruptcy protection on April 30, 2004 amidst significant liquidity constraints. After winning approval of its debtor-in-possession financing facility, Women First and its professionals engaged in extensive efforts to maximize asset value through liquidation efforts. Six of the pharmaceutical product lines were acquired through several spirited sales and auctions resulting in significantly higher value than originally projected. In accordance with the chapter 11 plan, a liquidating trustee has been appointed to, among other things, liquidate any remaining assets, prosecute avoidance actions and reconcile claims.